UK-based drugmaker, Clinigen, has announced plans to introduce its three cancer drugs in the Kenyan market.
In a statement, Clinigen Group Plc said it had granted Eisai Europe exclusive rights to seek licences from Kenyan authorities for the three brands, Halaven (eribulin), Fycompa (perampanel) and Lenvima (lenvatinib).
Clinigen’s South Africa managing director Benjamin Miny said: “We are able to leverage our extensive distribution network in the region and local expertise to enable access to these important medicines, helping to address the unmet medical needs of patients and their families across southern Africa.”
The agreement will also see Eisai seek regulatory approval for the three drugs in Namibia, Botswana, Zimbabwe, Zambia, Ghana, Nigeria, Uganda and Tanzania. It has since obtained approvals to sell Halaven and Fycompa in South Africa.